2023
Botulism mimicking Guillain‐Barre syndrome: The question of plasma exchange in an unusual case of acute paralysis
Campos J, Abels E, Rinder H, Tormey C, Jacobs J. Botulism mimicking Guillain‐Barre syndrome: The question of plasma exchange in an unusual case of acute paralysis. Journal Of Clinical Apheresis 2023, 38: 760-763. PMID: 37519071, DOI: 10.1002/jca.22081.Peer-Reviewed Original ResearchConceptsGuillain-Barré syndromeAcute flaccid paralysisFlaccid paralysisPlasma exchangeImmune-mediated polyradiculoneuropathyIntravenous immune globulinCranial nerve palsyGuillain-Barre syndromeCerebrospinal fluid analysisAppropriate therapeutic modalityCases of botulismAlbuminocytological dissociationNerve palsyRespiratory failureEmpiric administrationImmune globulinLaboratory featuresPrompt diagnosisIngestion/inhalationPoor outcomeAcute paralysisBotulinum toxinCommon causeTherapeutic modalitiesUnusual caseOptimizing Donor Chimerism Threshold for Next-Generation Sequencing Monitoring of Measurable Residual Disease Post-Allogeneic Stem Cell Transplantation for Myeloid Neoplasms
Puzo C, Tormey C, Rinder H, Siddon A. Optimizing Donor Chimerism Threshold for Next-Generation Sequencing Monitoring of Measurable Residual Disease Post-Allogeneic Stem Cell Transplantation for Myeloid Neoplasms. Transplantation And Cellular Therapy 2023, 29: 459.e1-459.e4. PMID: 37062510, DOI: 10.1016/j.jtct.2023.04.005.Peer-Reviewed Original ResearchConceptsAllogeneic stem cell transplantationStem cell transplantationDonor chimerismCell transplantationNGS testingPost allogeneic stem cell transplantationMeasurable residual diseaseNext-generation sequencingAcute myeloid leukemiaConditioning regimenRelated donorsMyelodysplastic syndromeResidual diseaseValidation cohortMyeloid leukemiaMyeloid neoplasmsNGS panelLogistic regressionPatientsChimerismSignificant predictorsCharacteristic curveTransplantationRegimenConservative thresholdQuantitative Risk for Single-Positive Lupus Anticoagulant Results With Different Anticoagulants
Khan W, Tormey C, Rinder H, Siddon A. Quantitative Risk for Single-Positive Lupus Anticoagulant Results With Different Anticoagulants. American Journal Of Clinical Pathology 2023, 159: 417-419. PMID: 36940149, DOI: 10.1093/ajcp/aqac183.Peer-Reviewed Original Research
2021
Concomitant factor VIII inhibitor and lupus anticoagulant in an asymptomatic patient
Jacobs JW, Gisriel SD, Iyer K, Rinder HM. Concomitant factor VIII inhibitor and lupus anticoagulant in an asymptomatic patient. Journal Of Thrombosis And Thrombolysis 2021, 53: 945-949. PMID: 34697688, PMCID: PMC8544916, DOI: 10.1007/s11239-021-02591-4.Peer-Reviewed Original ResearchConceptsPartial thromboplastin timeLupus anticoagulantFVIII inhibitorsAsymptomatic patientsFactor VIIIComprehensive hematologic evaluationLife-threatening hemorrhageTypical laboratory findingsDistinctive clinical presentationFactor VIII inhibitorsRisk of thrombosisSigns of hemorrhageSevere bleeding diathesisCoagulation factor VIIIImmunosuppressive therapyClinical presentationClinical symptomsPathologic antibodiesVIII inhibitorsLaboratory findingsHematologic evaluationUnique presentationBleeding diathesisThromboplastin timeAutoantibodiesIncreased complement activation is a distinctive feature of severe SARS-CoV-2 infection
Ma L, Sahu S, Cano M, Kuppuswamy V, Bajwa J, McPhatter J, Pine A, Meizlish M, Goshua G, Chang C, Zhang H, Price C, Bahel P, Rinder H, Lei T, Day A, Reynolds D, Wu X, Schriefer R, Rauseo A, Goss C, O’Halloran J, Presti R, Kim A, Gelman A, Dela Cruz C, Lee A, Mudd P, Chun H, Atkinson J, Kulkarni H. Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection. Science Immunology 2021, 6: eabh2259. PMID: 34446527, PMCID: PMC8158979, DOI: 10.1126/sciimmunol.abh2259.Peer-Reviewed Original ResearchConceptsSevere SARS-CoV-2 infectionSARS-CoV-2 infectionIntensive care unitComplement activationRespiratory failureEndothelial injuryCOVID-19Non-COVID cohortPersonalized clinical trialsAcute respiratory failureInvasive mechanical ventilationSevere COVID-19Tertiary care centerAlternative complement pathwayICU admissionCritical illnessCare unitMechanical ventilationRisk prognosticationWashington University SchoolWorse outcomesCare centerClinical trialsHigh riskPatients
2013
Pathology Consultation on Evaluating Prognosis in Incidental Monoclonal Lymphocytosis and Chronic Lymphocytic Leukemia
Siddon AJ, Rinder HM. Pathology Consultation on Evaluating Prognosis in Incidental Monoclonal Lymphocytosis and Chronic Lymphocytic Leukemia. American Journal Of Clinical Pathology 2013, 139: 708-712. PMID: 23690112, DOI: 10.1309/ajcplir4gzwx3xka.Peer-Reviewed Original ResearchMeSH KeywordsADP-ribosyl Cyclase 1Beta 2-MicroglobulinFlow CytometryGene Rearrangement, B-LymphocyteHumansImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionIncidental FindingsLeukemia, Lymphocytic, Chronic, B-CellLymphocytosisMaleMiddle AgedMutationPrognosisWatchful WaitingZAP-70 Protein-Tyrosine KinaseConceptsChronic lymphocytic leukemiaEarly-stage chronic lymphocytic leukemiaStage chronic lymphocytic leukemiaDisease progressionLymphocytic leukemiaImmunoglobulin heavy chain variable (IGHV) gene mutational statusMonoclonal B-cell lymphoproliferative disorderLaboratory evaluationOvert chronic lymphocytic leukemiaMonoclonal B-cell lymphocytosisB-cell lymphoproliferative disordersAggressive disease progressionSignificant disease progressionIndolent clinical courseSerum β2-microglobulinRoutine laboratory evaluationB-cell lymphocytosisZAP-70 expressionGene mutational statusMonoclonal lymphocytosisClinical courseExpectant observationLymphoproliferative disordersTherapeutic optionsPrognostic marker
2012
Neutrophil CD64 as a Diagnostic Marker in Neonatal Sepsis
Streimish I, Bizzarro M, Northrup V, Wang C, Renna S, Koval N, Li FY, Ehrenkranz R, Rinder HM, Bhandari V. Neutrophil CD64 as a Diagnostic Marker in Neonatal Sepsis. The Pediatric Infectious Disease Journal 2012, 31: 777-781. PMID: 22481422, PMCID: PMC3375383, DOI: 10.1097/inf.0b013e318256fb07.Peer-Reviewed Original ResearchNormalized CCND1 expression has prognostic value in mantle cell lymphoma
Siddon AJ, Torres R, Rinder HM, Smith BR, Howe JG, Tormey CA. Normalized CCND1 expression has prognostic value in mantle cell lymphoma. British Journal Of Haematology 2012, 158: 551-553. PMID: 22671703, DOI: 10.1111/j.1365-2141.2012.09181.x.Peer-Reviewed Original Research
2011
Senior Pathology Resident In-Service Examination Scores Correlate With Outcomes of the American Board of Pathology Certifying Examinations
Rinder HM, Grimes MM, Wagner J, Bennett BD. Senior Pathology Resident In-Service Examination Scores Correlate With Outcomes of the American Board of Pathology Certifying Examinations. American Journal Of Clinical Pathology 2011, 136: 499-506. PMID: 21917671, DOI: 10.1309/ajcpa7o4bbuglsww.Peer-Reviewed Original ResearchConceptsLowest quartileResident In-Service ExaminationRISE scoresAmerican BoardGraduate Medical Education (ACGME) Outcome ProjectSimilar quartilesClinical pathologyOutcomes ProjectScore correlateQuartileLowest quartile scoresQuartile scoresIn-Service ExaminationScoresExaminationPathologyPathology knowledgeAccreditation CouncilCertifying ExaminationRiskResidents
2006
Cardiac surgery in a patient with heparin-induced thrombocytopenia--cautions with use of the direct thrombin inhibitor, argatroban.
Kurup V, Transue S, Wu Y, Rinder HM, Barash P, Dewar M. Cardiac surgery in a patient with heparin-induced thrombocytopenia--cautions with use of the direct thrombin inhibitor, argatroban. Connecticut Medicine 2006, 70: 245-50. PMID: 16768071.Peer-Reviewed Original ResearchConceptsDirect thrombin inhibitorCardiopulmonary bypassCardiac surgeryThrombin inhibitorsCoronary bypass graft surgeryBypass graft surgeryAortic valve replacementNumber of patientsPresent case reportGraft surgeryValve replacementCase reportPharmacologic basisBlood productsHeparin substitutePatientsSurgeryArgatrobanPrevious exposurePertinent reportsHeparinThrombocytopeniaSubstantial numberInhibitorsReport
2004
Utility of in vitro tests in predicting the in vivo viability of stored PLTs
Murphy S, Rinder H, Smith B. Utility of in vitro tests in predicting the in vivo viability of stored PLTs. Transfusion 2004, 44: 618-619. PMID: 15043581, DOI: 10.1111/j.1537-2995.2004.00355.x.Peer-Reviewed Original Research
2001
The Effects of Heparin, Protamine, and Heparin/Protamine Reversal on Platelet Function Under Conditions of Arterial Shear Stress
Griffin M, Rinder H, Smith B, Tracey J, Kriz N, Li C, Rinder C. The Effects of Heparin, Protamine, and Heparin/Protamine Reversal on Platelet Function Under Conditions of Arterial Shear Stress. Anesthesia & Analgesia 2001, 93: 20-27. PMID: 11429331, DOI: 10.1097/00000539-200107000-00005.Peer-Reviewed Original ResearchConceptsCollagen-induced thrombus formationPlatelet hemostasis timePartial thromboplastin timeAntiplatelet effectProthrombin timeAntithrombin effectPlatelet activationProtamine reversalPlatelet functionDirect antiplatelet effectCollagen-dependent platelet activationDirect thrombin inhibitorL-arginyl-chloromethyl ketoneClot Signature AnalyzerEffect of heparinCollagen-induced platelet activationEffect of protamineArterial shear stressBlood lossCardiopulmonary bypassPlatelet dysfunctionProtamine ratioPlatelet aggregometryAnticoagulant effectThromboplastin timeXenotransplantation of immunodeficient mice with mobilized human blood CD34+ cells provides an in vivo model for human megakaryocytopoiesis and platelet production
Perez L, Rinder H, Wang C, Tracey J, Maun N, Krause D. Xenotransplantation of immunodeficient mice with mobilized human blood CD34+ cells provides an in vivo model for human megakaryocytopoiesis and platelet production. Blood 2001, 97: 1635-1643. PMID: 11238102, DOI: 10.1182/blood.v97.6.1635.Peer-Reviewed Original ResearchConceptsPeripheral blood stem cellsHuman peripheral blood stem cellsPlatelet productionVivo modelStudy of megakaryocytopoiesisCFU-MKHuman megakaryocytopoiesisImmunodeficient miceBone marrowHuman plateletsExogenous cytokinesNOD/SCID miceHuman hematopoiesisBlood stem cellsHuman cell engraftmentPlatelet developmentNonobese diabetic/Lymphoid lineageStem cellsHuman blood CD34MegakaryocytopoiesisPeripheral bloodCytokine stimulationMurine recipientsThrombin stimulation
2000
Cocaine, HIV, and their cardiovascular effects: is there a role for ACE-inhibitor therapy?
Margolin A, Avants S, Setaro J, Rinder H, Grupp L. Cocaine, HIV, and their cardiovascular effects: is there a role for ACE-inhibitor therapy? Drug And Alcohol Dependence 2000, 61: 35-45. PMID: 11064182, DOI: 10.1016/s0376-8716(00)00124-1.Peer-Reviewed Original ResearchConceptsACE inhibitor therapyCocaine abuseCocaine useAngiotensin converting enzyme (ACE) inhibitorsDiastolic heart functionNew pharmacologic approachesLevels of dopamineConverting Enzyme InhibitorsCocaine-abusing populationCocaine-abusing patientsConsiderable clinical utilityClass of agentsPlatelet activation studiesCardiovascular sequelaeHIV patientsCardiovascular effectsHIV diseaseHIV-positiveACE inhibitorsHIV serostatusRisk factorsPharmacologic approachesPlatelet abnormalitiesClinical utilityHeart functionHemosiderosis in a Normal Child Secondary to Oral Iron Medication
Pearson H, Ehrenkranz R, Rinder H, Riely C. Hemosiderosis in a Normal Child Secondary to Oral Iron Medication. Pediatrics 2000, 105: 429-430. PMID: 10654969, DOI: 10.1542/peds.105.2.429.Peer-Reviewed Original Research
1999
Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardiopulmonary Bypass
Fitch J, Rollins S, Matis L, Alford B, Aranki S, Collard C, Dewar M, Elefteriades J, Hines R, Kopf G, Kraker P, Li L, O’Hara R, Rinder C, Rinder H, Shaw R, Smith B, Stahl G, Shernan S. Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardiopulmonary Bypass. Circulation 1999, 100: 2499-2506. PMID: 10604887, DOI: 10.1161/01.cir.100.25.2499.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBlood Loss, SurgicalCardiopulmonary BypassCognition DisordersComplement ActivationComplement C5Complement Membrane Attack ComplexCoronary Artery BypassCoronary DiseaseCreatine KinaseHumansInflammationIsoenzymesMiddle AgedMyocardial Reperfusion InjuryPostoperative ComplicationsProspective StudiesPsychological TestsSingle-Chain AntibodiesConceptsMini-Mental State ExaminationPathological complement activationCardiopulmonary bypassBlood lossMyocardial injuryC5 inhibitionTissue injuryCoronary artery bypass graft surgeryComplement inhibitorsArtery bypass graft surgeryComplement activationCognitive deficitsSingle-chain antibodyC5 complement inhibitorNew cognitive deficitsSignificant dose-dependent inhibitionBypass graft surgeryPostoperative blood lossPostoperative myocardial injurySystemic inflammatory responseComplement-mediated inflammationLeukocyte CD11b expressionNovel therapeutic strategiesComplement hemolytic activityDose-dependent fashionOptimal dosing and triggers for prophylactic use of platelet transfusions
Rinder H, Arbini A, Snyder E. Optimal dosing and triggers for prophylactic use of platelet transfusions. Current Opinion In Hematology 1999, 6: 437. PMID: 10546800, DOI: 10.1097/00062752-199911000-00015.Peer-Reviewed Original ResearchConceptsProphylactic platelet transfusionsPlatelet transfusionsPlatelet transfusion guidelinesPlatelet transfusion practicesPlatelet transfusion supportAdequate platelet inventoryTransfusion intervalTransfusion guidelinesTransfusion supportMyeloablative therapyOptimal dosingTransfusion practiceProphylactic useThrombocytopenic patientsOutpatient supportPatient outcomesInpatient settingPlatelet dosePlatelet dosesTransfusionSmall dosesPlatelet inventoryPatientsDosesRecent studiesRole of C3 Cleavage in Monocyte Activation During Extracorporeal Circulation
Rinder C, Rinder H, Johnson K, Smith M, Lee D, Tracey J, Polack G, Higgins P, Yeh C, Smith MD B. Role of C3 Cleavage in Monocyte Activation During Extracorporeal Circulation. Circulation 1999, 100: 553-558. PMID: 10430771, DOI: 10.1161/01.cir.100.5.553.Peer-Reviewed Original ResearchConceptsMonocyte activationC5b-9CD11b upregulationComplement inhibitionExtracorporeal circulationPlatelet activationTerminal complement inhibitionMonocyte-platelet conjugatesComplement regulatory protein CD46Early complement componentsPMN elastase releaseGeneration of C3aMicrograms/mLCardiopulmonary bypassBlood cell activationPMN activationElastase releaseCell activationHuman volunteersMicrograms/Complement activationPrevents plateletComplement componentsWhole bloodCommon pathway
1998
Platelet activation and its detection during the preparation of platelets for transfusion
Rinder H, Ault K. Platelet activation and its detection during the preparation of platelets for transfusion. Transfusion Medicine Reviews 1998, 12: 271-287. PMID: 9798270, DOI: 10.1016/s0887-7963(98)80003-5.Peer-Reviewed Original ResearchStroke in a Neonate Heterozygous for Factor V Leiden
Varelas P, Sleight B, Rinder H, Sze G, Ment L. Stroke in a Neonate Heterozygous for Factor V Leiden. Pediatric Neurology 1998, 18: 262-264. PMID: 9568926, DOI: 10.1016/s0887-8994(97)00166-5.Peer-Reviewed Original Research